These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 32407368)

  • 1. Correction: Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)-A concordance comparison cohort analysis.
    PLOS ONE Staff
    PLoS One; 2020; 15(5):e0233532. PubMed ID: 32407368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)-A concordance comparison cohort analysis.
    Wu WP; Wu HK; Chen CJ; Lee CW; Chen ST; Chen DR; Chou CT; Mok CW; Lai HW
    PLoS One; 2019; 14(10):e0222917. PubMed ID: 31600220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.
    Vriens BE; de Vries B; Lobbes MB; van Gastel SM; van den Berkmortel FW; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Smidt ML; Peer PG; Aarts MJ; Tjan-Heijnen VC;
    Eur J Cancer; 2016 Jan; 52():67-76. PubMed ID: 26650831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Performances of breast magnetic resonance imaging in the context of neoadjuvant chemotherapy for breast cancer to predict pathological complete response].
    Brisson C; Diguisto C; Vildé A; Body G; Arbion F; Leveque J; Ouldamer L
    J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):147-154. PubMed ID: 28403971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the Diagnostic Accuracy of Magnetic Resonance Imaging with Sonography in the Prediction of Breast Cancer Tumor Size: A Concordance Analysis with Histopathologically Determined Tumor Size.
    Lai HW; Chen DR; Wu YC; Chen CJ; Lee CW; Kuo SJ; Chen ST; Wu HK
    Ann Surg Oncol; 2015 Nov; 22(12):3816-23. PubMed ID: 25707494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional ultrasonography of the breast; An adequate replacement for MRI in neoadjuvant chemotherapy tumour response evaluation? - RESPONDER trial.
    van Egdom LSE; Lagendijk M; Heijkoop EHM; Koning AHJ; van Deurzen CHM; Jager A; van Lankeren W; Koppert LB
    Eur J Radiol; 2018 Jul; 104():94-100. PubMed ID: 29857873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Which factors influence MRI-pathology concordance of tumour size measurements in breast cancer?
    Rominger M; Berg D; Frauenfelder T; Ramaswamy A; Timmesfeld N
    Eur Radiol; 2016 May; 26(5):1457-65. PubMed ID: 26268905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Hamy AS; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2016; 11(7):e0159123. PubMed ID: 27388624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients.
    Bouzón A; Acea B; Soler R; Iglesias Á; Santiago P; Mosquera J; Calvo L; Seoane-Pillado T; García A
    Radiol Oncol; 2016 Mar; 50(1):73-9. PubMed ID: 27069452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
    Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
    Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The assessment of breast cancer response to neoadjuvant chemotherapy: comparison of magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
    Park JS; Moon WK; Lyou CY; Cho N; Kang KW; Chung JK
    Acta Radiol; 2011 Feb; 52(1):21-8. PubMed ID: 21498321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast MRI and tumour biology predict axillary lymph node response to neoadjuvant chemotherapy for breast cancer.
    Al-Hattali S; Vinnicombe SJ; Gowdh NM; Evans A; Armstrong S; Adamson D; Purdie CA; Macaskill EJ
    Cancer Imaging; 2019 Dec; 19(1):91. PubMed ID: 31878958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy.
    Williams M; Eatrides J; Kim J; Talwar H; Esposito N; Szabunio M; Ismail-Khan R; Kiluk J; Lee M; Laronga C; Khakpour N
    Am J Surg; 2013 Oct; 206(4):567-73. PubMed ID: 23809673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy.
    Belli P; Costantini M; Malaspina C; Magistrelli A; LaTorre G; Bonomo L
    Clin Radiol; 2006 Nov; 61(11):946-53. PubMed ID: 17018307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring the size and response of locally advanced breast cancers to neoadjuvant chemotherapy (weekly paclitaxel and epirubicin) with serial enhanced MRI.
    Cheung YC; Chen SC; Su MY; See LC; Hsueh S; Chang HK; Lin YC; Tsai CS
    Breast Cancer Res Treat; 2003 Mar; 78(1):51-8. PubMed ID: 12611457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: A specific expression profile of LC3B and p62 is associated with nonresponse to neoadjuvant chemotherapy in esophageal adenocarcinomas.
    Adams O; Janser FA; Dislich B; Berezowska S; Humbert M; Seiler CA; Kröll D; Slotta-Huspenina J; Feith M; Ott K; Tschan MP; Langer R
    PLoS One; 2019; 14(10):e0224832. PubMed ID: 31665193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast magnetic resonance imaging use in patients undergoing neoadjuvant chemotherapy is associated with less mastectomies in large ductal cancers but not in lobular cancers.
    Vriens IJH; Keymeulen K; Lobbes MBI; van Bommel ACM; Nieuwenhuijzen GAP; Smidt ML; Boersma LJ; van Dalen T; Smorenburg CH; Struikmans H; Siesling S; Voogd AC; Tjan-Heijnen VCG;
    Eur J Cancer; 2017 Aug; 81():74-80. PubMed ID: 28618304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDG-PET/CT and MRI for Evaluation of Pathologic Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer: A Meta-Analysis of Diagnostic Accuracy Studies.
    Sheikhbahaei S; Trahan TJ; Xiao J; Taghipour M; Mena E; Connolly RM; Subramaniam RM
    Oncologist; 2016 Aug; 21(8):931-9. PubMed ID: 27401897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating the prediction value of multiparametric magnetic resonance imaging at 3 T in response to neoadjuvant chemotherapy in breast cancer.
    Minarikova L; Bogner W; Pinker K; Valkovič L; Zaric O; Bago-Horvath Z; Bartsch R; Helbich TH; Trattnig S; Gruber S
    Eur Radiol; 2017 May; 27(5):1901-1911. PubMed ID: 27651141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy.
    Wasser K; Sinn HP; Fink C; Klein SK; Junkermann H; Lüdemann HP; Zuna I; Delorme S
    Eur Radiol; 2003 Jun; 13(6):1213-23. PubMed ID: 12764635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.